| Patient | Martin Luther |
|---|---|
| Date of birth | 1982-11-19 |
| Identifiers | MRN HR-RE004-SYN; SSN (made up) 000-04-3892 |
| Document date | 2026-10-27 |
| Author | Ottilie Brandt-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Thirteen-week review: attacks, hearing, mood and stone prevention. [S]
Professor Luther returns five weeks after his six-week review. He has had no vertigo attack for eight weeks and has preached and lectured without one. The tinnitus is still there but quieter. He has done the printed balance exercises daily; the first appointment with the vestibular physical therapist is next week, because of a waiting list. He collected the 24-hour urine on an ordinary working day. He keeps the salt limit at home but not at dinners with guests, and he admits he drinks little water. His mood is clearly better: he sleeps seven hours, enjoys his work and his household again, and has had eight therapy sessions. He has no thoughts of harming himself. [S]
| Element | Detail |
|---|---|
| Attacks | None for eight weeks |
| Balance therapy | Home exercises; first therapist visit next week |
| Urine | 24-hour collection done |
| Mood | Better; PHQ-9 6 |
| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Positive | Quieter left-ear tinnitus; no fullness |
| Neurological | Negative | No vertigo; unsteadiness much less |
| Genitourinary | Negative | No flank pain |
| Psychiatric | Negative | Mood good; no suicidal ideation |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Meclizine 25 mg tablet, one by mouth up to every 8 hours during a severe vertigo attack only, for no more than 3 days at a time | every 8 hours as needed during a severe attack, at most 3 days at a time | Oral route | 2026-07-28 | active | S |
| Naproxen 500 mg tablet, one by mouth twice daily with food for up to 7 days for stone pain | twice daily with food for up to 7 days | Oral route | 2026-08-25 to 2026-09-01 | completed | S |
| Tamsulosin 0.4 mg capsule, one by mouth daily for up to 4 weeks or until the stone passes | once daily until the stone passes | Oral route | 2026-08-25 to 2026-09-03 | completed | S |
| Hydrochlorothiazide 25 mg tablet, one by mouth each morning | once daily in the morning | Oral route | 2026-08-11 | active | S |
| Sertraline 25 mg tablet, one by mouth each morning for one week | once daily in the morning | Oral route | 2026-08-11 to 2026-08-18 | completed | S |
| Sertraline 50 mg tablet, one by mouth each morning | once daily in the morning | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 175 | cm | S |
| 2026-10-27 | Body weight | 84.4 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 70 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-27 | Potassium [Moles/volume] in Serum or Plasma | 3.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-27 | Calcium [Mass/volume] in Serum or Plasma | 9.9 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 98 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-10-27 | Volume of 24 hour Urine | 1.6 | L/(24.h) | 2.5 or more for stone prevention | Low | S |
| 2026-10-27 | Calcium [Mass/time] in 24 hour Urine | 190 | mg/(24.h) | Below 250 in men | Normal | S |
| 2026-10-27 | Oxalate [Mass/time] in 24 hour Urine | 38 | mg/(24.h) | Below 40 | Normal | S |
| 2026-10-27 | Citrate [Mass/time] in 24 hour Urine | 410 | mg/(24.h) | 450 or more | Low | S |
| 2026-10-27 | Sodium [Moles/time] in 24 hour Urine | 140 | mmol/(24.h) | Below 100 for stone prevention | High | S |
| 2026-10-27 | Urate [Mass/time] in 24 hour Urine | 680 | mg/(24.h) | Below 800 in men | Normal | S |
| 2026-10-27 | Creatinine [Mass/time] in 24 hour Urine | 1750 | mg/(24.h) | 1,000 to 2,000 in men; checks completeness | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Blood pressure 120/78, pulse 70; weight 84.4 kg, BMI 27.6 |
| Neurological | No nystagmus; tandem gait steady; Romberg steady on foam with eyes closed |
| Psychiatric | Euthymic, reactive affect; no suicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent attacks of spinning vertigo for about three months, the worst twelve days ago, lasting hours, with roaring tinnitus, fullness and muffled hearing in the left ear and nausea, the tinnitus persisting between attacks; with low mood, poor sleep and loss of interest; cause not established at intake: an inner-ear disorder suspected, with vestibular migraine, vestibular schwannoma and posterior circulation stroke to be excluded and depression to be assessed; otology consultation requested | resolved | confirmed | R42 | S — Synthetic presenting problem anchored to his documented attacks of April and July 1527; superseded by the diagnoses at the second visit. |
| Ménière disease of the left ear, definite (AAO-HNS 2020 and Bárány Society criteria), with low-frequency sensorineural hearing loss and persistent tinnitus in the left ear; vestibular migraine considered and judged unlikely as the main cause; vestibular schwannoma excluded by MRI | active | confirmed | H81.02 | S — Synthetic modern diagnosis made at the otology consultation, linked to his documented attacks and to the retrospective diagnosis of Ménière disease (R). |
| Major depressive disorder, recurrent, moderate (DSM-5-TR), with low mood, poor sleep, loss of interest, guilt and fatigue for about two months, after earlier periods of spiritual crisis and low mood; no suicidal ideation | active | confirmed | F33.1 | S — Synthetic modern diagnosis linked to his documented Anfechtungen and low periods; not a claim that he was so diagnosed; the retrospective psychiatric readings are disputed (R). |
| Urinary stone disease: one stone passed spontaneously last year after severe pain; stone type and metabolic risk not yet known at intake | active | confirmed | Z87.442 | S — Synthetic modern problem anchored to his documented first stone in 1526. |
| Right distal ureteral stone, 5 mm, at the ureterovesical junction, with mild right hydronephrosis and renal colic; no infection; kidney function normal; managed with naproxen and tamsulosin; passed nine days later; resolved | resolved | confirmed | N20.1 | S — Synthetic acute problem anchored to his documented recurrent stones; this episode is not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Vertigo attack diary: number, duration, hearing, tinnitus, fullness, headache | Every visit | Completed today | No attacks for eight weeks; no headaches; Dizziness Handicap Inventory 18 (Dizziness Handicap Inventory in the notes; no LOINC code used) |
| Examination | Audiometry (pure-tone and speech) | At diagnosis; repeat at about three months and with any change in hearing | Completed today | Left low-frequency loss 30 to 35 dB; word recognition 92 percent left; right normal |
| Laboratory | Sodium, potassium, creatinine and calcium on a thiazide with an SSRI | Two to four weeks after starting, then every three to six months | Completed today | Sodium 137, potassium 3.8 mmol/L, creatinine 0.98 mg/dL, calcium 9.9 mg/dL |
| Referral | Vestibular rehabilitation for chronic imbalance | When imbalance persists between attacks | Deferred | Protocol deviation: referred at the six-week visit, but the first therapist appointment is next week because of a waiting list. He has done the printed home exercises daily, his balance has improved, and he has not fallen, so no harm resulted. Corrective action: the clinic now gives the home program at the time of referral and asks for a telephone slot when the wait is over three weeks |
| Medication safety | Intratympanic steroid for persistent disabling attacks | If attacks persist after about three months of noninvasive treatment | Not indicated | No attacks for eight weeks |
| Self-management | Sodium, caffeine and alcohol limits | Every visit | Completed today | 24-hour urine sodium 140 mmol, still high; dietitian referral |
| Laboratory | 24-hour urine for a recurrent stone former | About six weeks after the stone passed; then within six months of starting treatment | Completed today | Volume 1.6 L/day, calcium 190, oxalate 38, citrate 410 (low), uric acid 680 and creatinine 1,750 mg/day, sodium 140 mmol/day (high) |
| Laboratory | Repeat 24-hour urine on treatment | Within six months of starting prevention | Due | In about six months |
| Imaging | Kidney imaging for new stones | Yearly, or with symptoms | Up to date | Ultrasound five weeks ago clear |
| Survey | PHQ-9 | At least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 6, a 60 percent fall from 15 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit | Completed today | No suicidal ideation since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | No missed doses; no side effects |
| Self-management | Psychotherapy attendance | Weekly, then every two weeks | Completed today | Eight CBT sessions attended |
Goal progress:
Guideline basis: Clinical Practice Guideline: Ménière's Disease (2020); Medical Management of Kidney Stones: AUA Guideline (2014); Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Dietitian in two weeks. Vestibular therapy next week. Review in three months; 24-hour urine in six months. [S]